868771-57-7

Basic information

• Product Name: Melogliptin
• Synonyms: melogliptin;(2S,4S)-4-Fluoro-1-[2-[[(1R,3S)-3-(1H-1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]-2-pyrrolidinecarbonitrile;(2S,4S)-4-fluoro-1-[2-[[(1R,3S)-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile
• CAS NO: 868771-57-7
• Molecular Formula: C₁₅H₂₁FN₆O
• Molecular Weight: 320.37
• Mol File: 868771-57-7.mol

Chemical Properties

• Appearance: /
• Density: 1.44
• CAS DataBase Reference: Melogliptin(CAS DataBase Reference)
• NIST Chemistry Reference: Melogliptin(868771-57-7)
• EPA Substance Registry System: Melogliptin(868771-57-7)

Safety Data

• Hazardous Substances Data: 868771-57-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Melogliptin is used as an oral antihyperglycemic agent for the treatment of type 2 diabetes. It helps to control blood sugar levels by increasing the levels of incretin hormones, which in turn stimulate insulin release and decrease sugar production in the liver.
Used in Diabetes Management:
Melogliptin is used as a medication for managing type 2 diabetes, helping patients to maintain their blood sugar levels within a healthy range. It is an essential component of a comprehensive diabetes management plan, which may also include diet, exercise, and regular monitoring of blood sugar levels.
Common side effects of Melogliptin may include headache, upper respiratory tract infection, and urinary tract infection. It is crucial to follow the dosage instructions provided by a healthcare professional and to discuss the potential risks and benefits of using Melogliptin before starting treatment. Regular monitoring of blood sugar levels is also important while taking this medication.

Upstream product

• 1000616-36-3 (2S,4S)-1-{2-[(3S,1R)-3-(1H-1,2,4-triazol-1-ylmethyl)cyclopentyl-N-BOC-amino]acetyl}-4-fluoropyrrolidine-2-carboxamide 

Relevant articles and documents

NOVEL PROCESSES FOR THE PREPARATION OF DPP IV INHIBITORS

The present invention relates to novel processes for preparing DPP-IV inhibitors having the structure of formula I, and pharmaceutically acceptable salt thereof, which are useful for treatment of Type 2 diabetes.

NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION

The present invention relates to novel compounds useful as dipeptidyl peptidase IV (DPP-IV) inhibitors of the formula: (I) wherein Y is -S(O)m, -CH2-, CHF, or -CF2; m is 0, 1, or 2; X is a bond, C1-C5 alkyl (e.g., -CH2-), or -C(=0)-; the dotted line [----] in the carbocyclic ring represents an optional double bond; R1 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl, CN, -COOR3, CONR3R4, -OR3, -NR3R4, or NR3COR3; R2 is hydrogen, cyano, COOH, or an isostere of a carboxylic acid (such as SO3H, CONOH, B(OH)2, PO3R3R4, SO2NR3R4, tetrazole, -COOR3, -CONR3R4, NR3COR4, or -COOCOR3).